Medicine Atlas

How Healing Is Practiced
Sign In
Text size
100%
Theme
Condition

Hyperlysinemia

Endocrine, Nutritional and Metabolic Diseases

Hyperlysinemia is an autosomal recessive metabolic disorder marked by an abnormal rise of the amino acid lysine in the blood. It results from mutations in the AASS gene, which encodes alpha-aminoadipic semialdehyde synthase, an enzyme of lysine breakdown. Although the biochemical abnormality is striking, the condition appears to be benign and usually causes no health problems. Some patients have nevertheless been reported with behavioral abnormalities, delayed speech and language development, low muscle tone in infancy, intellectual disability, small head size, seizures, short attention span or short stature, and the disorder has been associated with ectopia lentis, a displaced eye lens. Because inheritance is autosomal recessive, an affected person carries two defective copies of the gene, one from each parent, while the parents usually carry a single copy and show no signs. The related condition saccharopinuria involves the same pathway.

Facts
Classification
ICD-10 Chapter
IV: Endocrine, Nutritional and Metabolic Diseases 1
Communicable or Non-communicable
Non-Communicable 1
Causative Agent
Causative Agent (category)
Genetic / Hereditary 1
Sources
1. Hyperlysinemia (Wikipedia)
  • Lead
    It is caused by mutations in AASS
  • Lead [disease-category]
    Hyperlysinemia is an autosomal recessive metabolic disorder
  • lead sentence 1
    Hyperlysinemia is an autosomal recessive metabolic disorder characterized by an abnormal increase of lysine in the blood, but appears to be benign.
View the Source
National Library of Medicine: MeSH Descriptor Data: Hyperlysinemias
National Library of MedicineMeSH tree number C10.228.140.163.100.380
Quote, MeSH tree number C10.228.140.163.100.380
A group of inherited metabolic disorders which have in common elevations of serum LYSINE levels.
View the Source
Comments (0)
No comments yet. Be the first to share a thought.
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.